Variable | Total | Dead* | Alive* | p Value |
CRP (mg/l) (at admission) | 58.6±57.9 | 61.1±54.7 | 57.3±64.3 | 0.72 |
CRP (mg/l) (after 2 weeks) | 28.0±49.3 | 45.0±26.7 | 20.7±78.2 | 0.013 |
CRP (mg/l) (peak level) | 139.9±94.1 | 160.8±86.5 | 130.5±107.3 | 0.12 |
IL-6 (ng/l) (at admission) | 45.3±112.1 | 43.5±134.5 | 46.3±42.2 | 0.90 |
IL-6 (ng/l) (after 2 weeks) | 24.1±42.5 | 39.1±25.4 | 17.9±65.2 | 0.011 |
Hb (g/l) | 112.2±17.3 | 109.8±17.5 | 113.2±16.9 | 0.48 |
Creatinine (μmol/l) | 95.3±66.6 | 123.2±26.7 | 81.4±104.1 | <0.001 |
eGFR (ml/min/1.73m2) (MDRD) | 81.0±41.2 | 67.3±44.1 | 87.0±29.6 | 0.016 |
TnT (ng/l) (at admission) | 106.9±226.1 | 156.1±204.7 | 82.3±259.3 | 0.083 |
TnT (ng/l) (after 2 weeks) | 75.7±124.2 | 109.7±104.4 | 61.1±157.6 | 0.048 |
Incremental TnT (%) | 40.8% | 44.4% | 39.3% | 0.60 |
NT-proBNP (ng/l) (at admission) | 3874.2±6868.4 | 8209.8±1962.6 | 1706.4±10314.3 | <0.001 |
NT-proBNP (ng/l) (after 2 weeks) | 2597.2±3363.6 | 4782.3±2042.7 | 1660.8±4633.1 | <0.001 |
Incremental NT-proBNP (%) | 41.7% | 30.6% | 46.4% | 0.11 |
CysC (mg/l) (at admission) | 1.34±0.67 | 1.73±0.35 | 1.15±0.94 | <0.001 |
CysC (mg/l) (after 2 weeks) | 1.45±0.81 | 0.99±0.65 | 0.66±0.99 | <0.001 |
CysC (>20% increase) (%) | 26.7% | 41.7% | 20.2% | 0.015 |
MR-proANP (pmol/l) (at admission) | 327.6±199.3 | 378.8±227.0 | 302.0±452.7 | 0.21 |
MR-proANP (pmol/l) (after 2 weeks) | 290.2±39.6 | 249.2±219.1 | 218.8±135.1 | 0.15 |
Copeptin (pmol/L) (at admission) | 23.3±29.0 | 30.1±24.3 | 19.9±59.2 | 0.17 |
Copeptin (pmol/L) (after 2 weeks) | 24.0±29.0 | 21.2±31.8 | 31.7±21.2 | 0.42 |
↵* After 5 years follow-up.
CRP, C reactive protein; eGFR, estimated glomerular filtration rate; IL-6, interleukin 6.